Shortly after the Spring Festival was over, many medical and pharmaceutical experts from Beijing and other places met in Wenshan discussing about intensive development of panax pseudoginseng and the "Phenomenon of Daphne", Wenshan. In the meantime, name of the Daphne Pharmaceutical Co., Ltd. Wenshan, Yunnan has been duly changed to Daphne Pharmaceutical Co., Ltd. Yunnan, who is stepping up absorption of investment subjects, in a bid to develop into a unique and professional modern enterprise integrating research, development, production and sales of panax pseudoginseng.  
        The Daphne Co., originally founded in May 1994 with registered capital of RMB 1.87 million yuan, is a private share-limited pharmaceutical enterprise owned by individuals. The enterprise started its business with production of common drugs. Now, it has developed into a powerhouse focused on R&D and production of high quality natural herbal products based on tPNS, including the tPNS tablets (Thrombosis Tablets), tPNS granules, panax                 pseudoginseng anthosin, Qiye Sleep Tablets, Heart Protection Capsules (compound tPNS capsules) and Menses Protection Tablets. What's notable, the Company took the lead in China to carry out research and development of the active monomer ingredients in tPNS, which led to invention of two high-tech products: Qishengli and Qishengjing. Now, the Company's stock capital has increased from RMB 1.87 million yuan to RMB 10.3 million yuan. As a certified national GMP-compliant enterprise and a high-tech enterprise of the Yunnan province, the Company is now a top 100 private enterprise of the Yunnan province, and reported sales of over RMB 100 million yuan last year.  
        According to Tang Xiuwen, Chairman of Daphne, after restructuring into a share-limited company, they will further enhance their capital operating ability, and make full use of the local panax pseudoginseng resource to develop high-tech natural drugs of diversified forms and varieties. Also, they will establish normalized corporate governance structure, modern enterprise system, market-oriented technical innovation system and management innovation mechanism. Through cooperation with the Yunnan Provincial Natural Drug Development Center, they will establish a Daphne research institute to continually improve the technical level of their products, and develop name brand product lineup, especially natural drugs for prevention and curing of cardio-cerebrovascular diseases, tumors, senile diseases and commonly-seen diseases. In the meantime, a national marketing system integrating advertising and PR network, product sales network and after-sale service network will be established, with the aim of realizing the following targets in two years: gross industrial output of RMB 350 million yuan, sales income of RMB 320 million yuan, profit & tax of RMB 700 million yuan, annual export earning of USD 1 million, and taking of a spot in national top 100 pharmaceutical enterprise and a top 100 industrial enterprise of the Yunnan Province in terms of comprehensive economic indices.